Vinge has advised Cellink AB, listed on Nasdaq Stockholm, in connection with the acquisition of all shares in Scienion Ag. Scienion is a life science company which focuses on precision dimensioning technology.
The Scienion group conducts operations in Germany, the United States, France and England. The purchase price for the shares, on a cash‑free and debt‑free basis, amounts to EUR 80 million, of which EUR 40 million is paid in cash and the remaining EUR 40 million is paid in newly issued Cellink shares. Closing is expected to take place at the end of August whereupon Cellink’s board of directors will adopt a resolution concerning the issue in kind in accordance with the authorization resolved at the company’s general meeting. Cellink intends to perform a new issue of shares in order to finance the cash element of the purchase price.
Vinge’s team has consisted of, among others, Anders Strid, Martin E Svanberg (M&A), Edin Agic (Capital Markets) as well as Anna Palmérus (Competition Law). Hengeler Mueller advised Cellink in Germany.